124 related articles for article (PubMed ID: 20409880)
1. Critical roles of (pro)renin receptor-bound prorenin in diabetes and hypertension: sallies into therapeutic approach.
Ichihara A; Itoh H; Inagami T
J Am Soc Hypertens; 2008; 2(1):15-9. PubMed ID: 20409880
[TBL] [Abstract][Full Text] [Related]
2. Activated prorenin as a therapeutic target for diabetic nephropathy.
Ichihara A; Sakoda M; Mito-Kurauchi A; Itoh H
Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S63-6. PubMed ID: 18922597
[TBL] [Abstract][Full Text] [Related]
3. Renin/prorenin receptor, (P)RR, in end-organ damage: current issues in 2007.
Inagami T; Nakagawa T; Ichihara A; Suzuki F; Itoh H
J Am Soc Hypertens; 2008; 2(4):205-9. PubMed ID: 20409904
[TBL] [Abstract][Full Text] [Related]
4. Renin, prorenin and the kidney: a new chapter in an old saga.
Ichihara A; Sakoda M; Kurauchi-Mito A; Kaneshiro Y; Itoh H
J Nephrol; 2009; 22(3):306-11. PubMed ID: 19557706
[TBL] [Abstract][Full Text] [Related]
5. Renin and prorenin activate pathways implicated in organ damage in human mesangial cells independent of angiotensin II production.
Melnyk RA; Tam J; Boie Y; Kennedy BP; Percival MD
Am J Nephrol; 2009; 30(3):232-43. PubMed ID: 19451703
[TBL] [Abstract][Full Text] [Related]
6. Involvement of receptor-bound prorenin in development of nephropathy in diabetic db/db mice.
Ichihara A; Sakoda M; Kurauchi-Mito A; Nishiyama A; Itoh H
J Am Soc Hypertens; 2008; 2(5):332-40. PubMed ID: 20409915
[TBL] [Abstract][Full Text] [Related]
7. Diabetic complications: a role for the prorenin-(pro)renin receptor-TGF-beta1 axis?
van den Heuvel M; Batenburg WW; Danser AH
Mol Cell Endocrinol; 2009 Apr; 302(2):213-8. PubMed ID: 18840499
[TBL] [Abstract][Full Text] [Related]
8. The (pro)renin receptor in health and disease.
Nguyen G
Ann Med; 2010; 42(1):13-8. PubMed ID: 20104654
[TBL] [Abstract][Full Text] [Related]
9. (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation.
Satofuka S; Ichihara A; Nagai N; Noda K; Ozawa Y; Fukamizu A; Tsubota K; Itoh H; Oike Y; Ishida S
Diabetes; 2009 Jul; 58(7):1625-33. PubMed ID: 19389828
[TBL] [Abstract][Full Text] [Related]
10. Continuous inhibition of the renin-angiotensin system and protection from hypertensive end-organ damage by brief treatment with angiotensin II type 1 receptor blocker in stroke-prone spontaneously hypertensive rats.
Takemori K; Ishida H; Ito H
Life Sci; 2005 Sep; 77(18):2233-45. PubMed ID: 15963533
[TBL] [Abstract][Full Text] [Related]
11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
12. The renin-angiotensin system, adrenomedullins and urotensin II in the kidney: possible renoprotection via the kidney peptide systems.
Takahashi K; Hirose T; Mori N; Morimoto R; Kohzuki M; Imai Y; Totsune K
Peptides; 2009 Aug; 30(8):1575-85. PubMed ID: 19477209
[TBL] [Abstract][Full Text] [Related]
13. [(Pro) renin receptor].
Ichihara A; Ito H
Nihon Rinsho; 2009 Apr; 67(4):675-80. PubMed ID: 19348227
[TBL] [Abstract][Full Text] [Related]
14. Drug discovery for overcoming chronic kidney disease (CKD): new therapy for CKD by a (pro)renin-receptor-blocking decoy peptide.
Ichihara A; Sakoda M; Kurauchi-Mito A; Narita T; Kinouchi K; Itoh H
J Pharmacol Sci; 2009 Jan; 109(1):20-3. PubMed ID: 19151536
[TBL] [Abstract][Full Text] [Related]
15. Short-term treatment of stroke-prone spontaneously hypertensive rats with an AT1 receptor blocker protects against hypertensive end-organ damage by prolonged inhibition of the renin-angiotensin system.
Hamaguchi R; Takemori K; Inoue T; Masuno K; Ito H
Clin Exp Pharmacol Physiol; 2008 Oct; 35(10):1151-5. PubMed ID: 18518883
[TBL] [Abstract][Full Text] [Related]
16. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in metabolic disorders: hypercholesterolaemia and diabetes].
Strawn WB
Drugs; 2002; 62 Spec No 1():31-41. PubMed ID: 12036387
[TBL] [Abstract][Full Text] [Related]
17. Human prorenin: pathophysiology and clinical implications.
Derkx FH; Schalekamp MA
Clin Exp Hypertens A; 1988; 10(6):1213-25. PubMed ID: 3066528
[TBL] [Abstract][Full Text] [Related]
18. Prorenin receptor blockers: effects on cardiovascular complications of diabetes and hypertension.
Ichihara A; Kaneshiro Y; Suzuki F
Expert Opin Investig Drugs; 2006 Oct; 15(10):1137-9. PubMed ID: 16989590
[TBL] [Abstract][Full Text] [Related]
19. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
Abassi Z; Winaver J; Feuerstein GZ
Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
[TBL] [Abstract][Full Text] [Related]
20. Relation between renin and prorenin in plasma from hypertensive patients and normal people: evidence for different renin:prorenin ratios.
Leckie BJ; Morton JJ
J Hum Hypertens; 1995 Jun; 9(6):493-6. PubMed ID: 7473533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
